Sangamo Therapeutics Inc (NASDAQ:SGMO) currently has a daily average trading volume of 13.10M but it saw 10708506 shares traded in last market. With a market cap of 190.73M USD, the company’s current market price of $0.92 came rising about 6.90 while comparing to the previous closing price of $0.86. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.48 and as low as $0.29. In the recent trading on the day, stock has struck highest price mark of $0.86 while lowest mark touched by it was $0.97.
Taking a look at 20-day trading activity of Sangamo Therapeutics Inc (SGMO) gives us an average price of $0.6490, while its current price level is -38.11% below from 52-week high level whereas it is 214.67% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.5408 while that of 200 days or SMA-200 reads an average of $0.5746. A closer look into the stock’s movement over the week reveals that its volatility is standing at 25.99% during that period while stretching the period over a month that increases to 27.59%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 61.67 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the RBC Capital Mkts which downgraded the stock as “Sector Perform” in its note to investors issued on November 03, 2023, recommending a price target of between $6 and $2 for it. BofA Securities downgraded its recommendation for the stock as a “Underperform” from “Neutral” on April 28, 2023 while assigning a price target range of $5-$1.50. Wedbush issued its recommendations for the stock as it upgraded the price target for the stock is $16.
Over the week, SGMO’s stock price is moving 29.97% up while it is 129.69% when we observe its performance for the past one month. Year-to-date it is 68.60% up and over the past year, the stock is showing a downside performance of -19.65%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.59 beaten by the consensus estimate of -0.32 for the same. In next quarter, company is expected to be making quarterly sales of $7.44M as analysts are expecting the sales for current fiscal year at $52.13M and seeing the company making $85.66M in sales next year. Moreover, analysts are in estimates of $15.12M for current-quarter revenue.
Currently, Sangamo Therapeutics Inc’s total number of outstanding shares is 208.22M with 7.71% of that held by the insiders while 50.11% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -472.99% and return on equity (ROE) at -194.05%. Stock’s beta reads 1.14. Stock has a price to book (P/B) ratio of 8.05 while price to sale or P/S ratio amounts to 15.53. Its return on asset (ROA) is -119.44% on average.
